Targeting the Sickle Cell Disease Cascade and the Shifting Approach to Care
English
Recorded Courses
hosted by Pharmacy Times Continuing Education (PTCE)
hosted by Pharmacy Times Continuing Education (PTCE)
attend it anywhere online
price
Free
Targeting the Sickle Cell Disease Cascade and the Shifting Approach to Care is organized by Pharmacy Times Continuing Education (PTCE),Release date: October 21, 2022,Expiration date: October 21, 2023,Description:,Sickle cell disease (SCD) affects about 100,000 people in the United States, mostly African Americans and has a per-patient lifetime cost of $1 million. As efforts are made to improve the efficiency and accuracy in treating SCD, focus of care has shifted from symptomatic treatment towards disease modification. Hydroxyurea has been the mainstay of therapy for more than 2 decades and is a ribonucleotide inductase inhibitor that induces HbF levels. A newly approved drug, voxelotor, reduces polymerization of HbS, increases hemoglobin and disrupts the disease cascade. Crizanlizumab binds to P-selectin on the surface of platelets and endothelium in blood vessels and blocks its interaction with P-selectin glycoprotein ligand 1, which reduces adhesion and platelet and neutrophil aggregation. Disease-modifying therapies can reduce the development of end organ damage and complications of SCD, lessen the incidence of painful, chronic symptoms, as well as reduce hospitalizations, lengths of stay, emergency room use, and blood transfusions. This in turn reduces overall costs while increasing quality of life. This symposium will supply managed care professionals with critical knowledge on SCD, therapeutic options for both symptomatic treatment and disease modification, and methods for providing the best possible care for patients by reducing healthcare resource utilization and improving patient outcomes. Embedded throughout the program are animation videos showcasing the pathophysiology and mechanisms of action of SCD and emerging therapies.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Illustrate the pathophysiology of sickle cell disease (SCD) cascade and the treatment challenges associated with the management of the disease and its comorbidities.,• Differentiate between treatments for acute management and disease modification and interpret clinical trial data and real-world evidence that supports treatment.,• Determine the cost of SCD and specific managed care strategies to maximize the efficiency of healthcare resource utilization while improving patient outcomes.